筋骨格障害治療薬の世界市場:リウマチ性関節炎、骨関節炎、骨粗鬆症、乾癬性関節炎、強直性脊椎炎、線維筋痛症

◆英語タイトル:Global Musculoskeletal Disorders Therapeutics Market 2016-2020
◆商品コード:IRTNTR10170
◆発行会社(調査会社):Technavio
◆発行日:2016年8月31日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、筋骨格障害治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、筋骨格障害治療薬の世界市場規模及び予測、種類別分析、投与経路(ROA)別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Musculoskeletal Disorders
Musculoskeletal disorders are the group of pain disorders or injuries that affect the body’s joints, muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back. The pain and discomfort vary with the severity of the condition. These disorders have a wide range of causes, but usually occur depending on the age, lifestyle, and occupation of an individual. Symptoms usually range from recurrent pain, stiffness, and swellings. X-rays and other medical imaging procedures may diagnose the condition. The treatment mainly depends on the severity of the condition. Apart from the drugs, physical therapy, and occupational therapy are also used to manage the condition.

Technavio’s analysts forecast the global musculoskeletal disorder therapeutics market to grow at a CAGR of 4.46% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global musculoskeletal disorder therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat musculoskeletal disorders including osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, psoriatic arthritis, and fibromyalgia.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Musculoskeletal Disorder Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• Johnson & Johnson
• Amgen
• Pfizer
• F. Hoffmann-La Roche
• Eli Lilly

[Other prominent vendors]
• 3SBio
• AB Sciences
• AbGenomics International
• Ablynx
• Adheron
• Akron Molecules AG
• Alder BioPharmaceuticals
• Amgen Astellas BioPharma K.K. in Japan
• Ampio Pharmaceuticals
• Antares Medical Services
• Astellas
• AstraZeneca
• Baxter
• Biocad
• Bioiberica
• Boehringer Ingelheim
• Bone Therapeutics
• Can-Fite BioPharma
• Celgene
• Celltrion
• Cellular Biomedicine
• Cerapedics
• ChemoCentryx
• Chugai Pharmaceutical
• Coherus Biosciences
• Daiichi Sankyo
• Dong-A ST
• Edding Pharm
• Eisai
• Epirus
• Eupraxia Pharmaceuticals
• Flexion Therapeutics
• Galapagos NV
• Gedeon Richter
• Gilead Sciences
• GlaxoSmithKline
• Histogenics
• IBSA Institut Biochimique
• iCeutica
• Iltoo Pharma
• Incyte
• Innovative Med Concepts
• Iroko Pharmaceuticals
• ISTO Technologies
• KaloBios Pharmaceuticals
• KAN Research Institute
• Kang Stem Biotech
• Kitov Pharmaceuticals
• Lexicon Pharmaceuticals
• LG Life Sciences
• MEDIPOST
• Medivir
• Merck
• Mereo
• Mesoblast
• MOCHIDA PHARMACEUTICAL
• MorphoSys
• Morphotek
• Mycenax
• Neomed Institute
• Novartis
• Omeros
• OrthoTrophix
• Osteologix
• OxyPharma
• PFEnex
• Philogen
• PhytoHealth
• Plexxikon
• PLx Pharma
• Protalex
• Proximagen
• Radius Health
• Regeneron Pharmaceuticals
• Samsung Bioepis
• Samumed
• Sandoz
• Sanofi
• SantoSolve AS
• Steminent Biotherapeutics
• Stempeutics Research
• Taiwan Liposome Company
• Takeda
• Tarsa Therapeutics
• Techfields Pharma
• Tetec AG
• TheraMAB
• TiGenix
• TissueGene
• Tonix Pharmaceuticals
• Translational Biosciences
• UCB
• Vericel
• Vertex Pharmaceuticals
• Vitaeris
• Winston Laboratories
• Zosano Pharma

[Market driver]
• Tentative approval of advanced drugs
• For a full, detailed list, view our report

[Market challenge]
• Growing preference toward surgeries
• For a full, detailed list, view our report

[Market trend]
• Ongoing active clinical trials for biosimilars
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by disease type
• Rheumatoid arthritis
• Osteoarthritis
• Osteoporosis
• Psoriatic arthritis
• Ankylosing spondylitis
• Fibromyalgia

PART 08: Global rheumatoid arthritis drugs market
• Market overview

PART 09: Global osteoarthritis drugs market
• Market overview

PART 10: Global osteoporosis drugs market
• Market overview

PART 11: Global ankylosing spondylitis drugs market
• Market overview

PART 12: Global psoriatic arthritis drugs market
• Market overview

PART 13: Global fibromyalgia drugs market
• Market overview

PART 14: Market segmentation by type of molecule
• Biologics
• Small molecules

PART 15: Market segmentation by route of administration
• Parenteral
• Topical
• Oral

PART 16: Geographical segmentation
• Global musculoskeletal disorder therapeutics market by geography 2015-2020
• Musculoskeletal disorders therapeutics market in Americas
• Musculoskeletal disorders therapeutics market in EMEA
• Musculoskeletal disorders therapeutics market in APAC

PART 17: Market drivers
• High growth potential of mAbs
• Unmet needs of therapeutics
• Tentative approval of advanced drugs
• Technological advancements in medical imaging
• Combination therapies

PART 18: Impact of drivers

PART 19: Market challenges
• Non-adherence to treatment regimen
• Growing preference toward surgeries
• Multiple patent expiries

PART 20: Impact of drivers and challenges

PART 21: Market trends
• Focus on regenerative medicines
• Ongoing active clinical trials for biosimilars
• Growing focus toward abuse-resistant novel drugs

PART 22: Vendor landscape
• Competitive scenario

PART 23: Key vendor analysis
• AbbVie
• Johnson & Johnson
• Amgen
• Pfizer
• F. Hoffmann-La Roche
• Eli Lilly
• Other prominent vendors

PART 24: Appendix
• List of abbreviations

PART 25: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key customer segments for musculoskeletal disorder therapeutics
Exhibit 03: Impact of biologics on various sectors
Exhibit 04: Pipeline portfolio: Global rheumatoid arthritis drugs market
Exhibit 05: Pipeline portfolio: Global osteoarthritis drugs market
Exhibit 06: Pipeline portfolio: Global osteoporosis drugs market
Exhibit 07: Pipeline portfolio: Global psoriatic arthritis drugs market
Exhibit 08: Pipeline portfolio: Global fibromyalgia drugs market
Exhibit 09: Pipeline portfolio: Global ankylosing spondylitis drugs market
Exhibit 10: Global musculoskeletal disorder therapeutics market 2015-2020 ($ billions)
Exhibit 11: Patient assistance programs offered by companies
Exhibit 12: CAM therapies for rheumatoid arthritis
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of global musculoskeletal disorder therapeutics market
Exhibit 15: Segmentation of global musculoskeletal disorder therapeutics market by revenue 2015
Exhibit 16: Opportunities in rheumatoid arthritis drugs industry
Exhibit 17: Global rheumatoid arthritis drugs market 2015-2020 ($ billions)
Exhibit 18: Unmet medical needs with current osteoarthritis treatments
Exhibit 19: Global osteoarthritis drugs market 2015-2020 ($ billions)
Exhibit 20: Global osteoporosis drugs market 2015-2020 ($ billions)
Exhibit 21: Global ankylosing spondylitis drugs market 2015-2020 ($ billions)
Exhibit 22: Global psoriatic arthritis drugs market 2015-2020 ($ billions)
Exhibit 23: Global fibromyalgia drugs market 2015-2020 ($ billions)
Exhibit 24: Segmentation of global musculoskeletal disorder therapeutics market by type of molecules 2015
Exhibit 25: Segmentation of global musculoskeletal disorder therapeutics market by ROA 2015
Exhibit 26: Global musculoskeletal disorder therapeutics market by geography 2015-2020
Exhibit 27: Global musculoskeletal disorder therapeutics market segmentation by geography 2015-2020 ($ billions)
Exhibit 28: Global share of musculoskeletal disorders therapeutics market by geography 2015
Exhibit 29: Global musculoskeletal disorder therapeutics market: Country analysis based on revenue and growth rate
Exhibit 30: Musculoskeletal disorders therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 31: Musculoskeletal disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 32: Musculoskeletal disorders therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 33: Few of the late-stage mAbs under development for various musculoskeletal disorders
Exhibit 34: Impact of drivers
Exhibit 35: Approval and patent expiries of top selling biologics
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Key vendors ranking 2015
Exhibit 38: Geographical presence of key vendors
Exhibit 39: Competitive scenario of global musculoskeletal disorder therapeutics market vendors 2015-2020
Exhibit 40: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 41: AbbVie: Geographical segmentation of Humira 2015
Exhibit 42: AbbVie: Metrics analysis
Exhibit 43: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 44: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 45: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 46: Johnson & Johnson: YoY revenue and growth rate of Stelara 2013-2015 ($ billions)
Exhibit 47: Johnson & Johnson: Metrics analysis
Exhibit 48: Amgen: YoY revenue and growth rate of Enbrel (US and Canada) 2013-2015 ($ billions)
Exhibit 49: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ billions)
Exhibit 50: Amgen: Geographical segmentation of Prolia 2015
Exhibit 51: Amgen: Metrics analysis
Exhibit 52: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 53: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 54: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 55: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ billions)
Exhibit 56: Pfizer: YoY revenue and growth rate of Xeljanz 2013-2015 ($ millions)
Exhibit 57: Pfizer: Metrics analysis
Exhibit 58: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 59: F. Hoffmann-La Roche: Geographical segmentation of MabThera/Rituxan by revenue 2015
Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 61: F. Hoffmann-La Roche: Geographical segmentation of Actemra/RoActemra by revenue 2015
Exhibit 62: F. Hoffmann-La Roche: Metrics analysis
Exhibit 63: Eli Lilly: YoY revenue and growth rate of Cymbalta 2013-2015 ($ billions)
Exhibit 64: Eli Lilly: YoY revenue and growth rate of Evista 2013-2015 ($ billions)
Exhibit 65: Eli Lilly: Geographical segmentation of Evista 2015
Exhibit 66: Eli Lilly: YoY revenue and growth rate of Forteo 2013-2015 ($ billions)
Exhibit 67: Eli Lilly: Geographical segmentation of Forteo 2015
Exhibit 68: Eli Lilly: Metrics analysis



【掲載企業】

AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche, Eli Lilly, 3SBio, AB Sciences, AbGenomics International, Ablynx, Adheron, Akron Molecules AG, Alder BioPharmaceuticals, Amgen Astellas BioPharma K.K. in Japan, Ampio Pharmaceuticals, Antares Medical Services, Astellas, AstraZeneca, Baxter, Biocad, Bioiberica, Boehringer Ingelheim, Bone Therapeutics, Can-Fite BioPharma, Celgene, Celltrion, Cellular Biomedicine, Cerapedics, ChemoCentryx, Chugai Pharmaceutical, Coherus Biosciences, Daiichi Sankyo, Dong-A ST, Edding Pharm, Eisai, Epirus, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gedeon Richter, Gilead Sciences, GlaxoSmithKline, Histogenics, IBSA Institut Biochimique, iCeutica, Iltoo Pharma, Incyte, Innovative Med Concepts, Iroko Pharmaceuticals, ISTO Technologies, KaloBios Pharmaceuticals, KAN Research Institute, Kang Stem Biotech, Kitov Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, MEDIPOST, Medivir, Merck, Mereo, Mesoblast, MOCHIDA PHARMACEUTICAL, MorphoSys, Morphotek, Mycenax, Neomed Institute, Novartis, Omeros, OrthoTrophix, Osteologix, OxyPharma, PFEnex, Philogen, PhytoHealth, Plexxikon, PLx Pharma, Protalex, Proximagen, Radius Health, Regeneron Pharmaceuticals, Samsung Bioepis, Samumed, Sandoz, Sanofi, SantoSolve AS, Steminent Biotherapeutics, Stempeutics Research, Taiwan Liposome Company, Takeda, Tarsa Therapeutics, Techfields Pharma, Tetec AG, TheraMAB, TiGenix, TissueGene, Tonix Pharmaceuticals, Translational Biosciences, UCB, Vericel, Vertex Pharmaceuticals, Vitaeris, Winston Laboratories, Zosano Pharma.

【レポートのキーワード】

筋骨格障害治療薬、リウマチ性関節炎治療薬、骨関節炎治療薬、骨粗鬆症治療薬、乾癬性関節炎治療薬、強直性脊椎炎治療薬、線維筋痛症治療薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[筋骨格障害治療薬の世界市場:リウマチ性関節炎、骨関節炎、骨粗鬆症、乾癬性関節炎、強直性脊椎炎、線維筋痛症]販売に関する免責事項
★調査レポート[筋骨格障害治療薬の世界市場:リウマチ性関節炎、骨関節炎、骨粗鬆症、乾癬性関節炎、強直性脊椎炎、線維筋痛症]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆